Latest News-Insilico Medicine Mediaroom_Page

Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders

CAMBRIDGE, Mass., June 22, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical...

2026-06-22 12:37 860

Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics

CAMBRIDGE, Mass. and HONG KONG, June 17, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: ...

2026-06-17 21:00 3786

Insilico Medicine and Human Longevity Announce Collaboration to Co-Develop Industry-First AI Foundation Model for Longevity Science

Cambridge, Mass., May 26, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-...

2026-05-26 21:41 7644

Insilico Medicine and Ribo Enter Strategic Collaboration Agreement: Leveraging AI Platform and Automated Lab for End-to-End Empowerment of RNA Interference and Oligonucleotide Therapeutics Development

SHANGHAI, May 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a biotechnology co...

2026-05-12 20:30 3949

Insilico's Rentosertib Inhalation Solution Receives IND Clearance for the World's First AI-Driven Candidate to Enter Direct-to-Lung Clinical Study

* Following positive Phase IIa results for oral Rentosertib in GENESIS-IPF with good tolerability...

2026-04-29 09:00 4509

Generative AI Leap: Insilico Medicine Nominates First Preclinical Candidate in the UAE

* For its 30th PCC anniversary, Insilico Medicine nominated ISM0387, the first UAE-based preclini...

2026-04-24 21:00 3438

Nature Reviews Drug Discovery | Target Identification and Assessment in the Era of AI

CAMBRIDGE, Mass., April 22, 2026 /PRNewswire/ -- Target identification is the first and perhaps mos...

2026-04-22 21:00 4235

Insilico Medicine Announces Industry's First Longevity Board to Accelerate AI-Driven Aging Research for Drug Discovery

CAMBRIDGE, Mass., April 21, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinica...

2026-04-21 21:05 5497

Insilico Medicine Announces Global R&D Collaboration with Lilly

AI-driven collaboration includes an exclusive worldwide license for a portfolio of programs spannin...

2026-03-30 08:30 5980

Insilico Medicine and Tenacia Biotechnology Expand AI-Driven CNS Collaboration with Deal Value Up to US$94.75 Million

CAMBRIDGE, Mass., March 26, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinica...

2026-03-26 22:08 6491

Insilico Medicine and ASKA Pharmaceutical Expand Partnership to Discover Novel Targets for Women's Health

CAMBRIDGE, Mass., March 24, 2026 /PRNewswire/ -- Insilico Medicine (3696.HK), a clinical-stage drug...

2026-03-24 18:29 4030

Insilico Medicine Launches PandaClaw: Empowering Biologists with Agentic AI for Therapeutic Discovery

CAMBRIDGE, Mass., March 23, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage g...

2026-03-23 20:30 5305

Insilico Medicine to Announce 2025 Financial Results on March 30, 2026

CAMBRIDGE, Mass., March 13, 2026 /PRNewswire/ -- Insilico Medicine (HKEX: 3696.HK, "Insilico" or th...

2026-03-13 21:59 9577

Insilico and TaiGen Achieve Milestone in Collaboration: Out-Licensed CKD Anemia Candidate ISM4808 Completes first human enrollment and dosing in Phase I clinical trial

CAMBRIDGE, Mass., March 5, 2026 /PRNewswire/ -- Insilico Medicine (Insilico Medicine, HKEX: 03696),...

2026-03-06 18:53 6646

Insilico Medicine and Liquid AI Announce Strategic Partnership Delivering Lightweight Scientific Foundation Models for Drug Discovery

Single 2.6B-parameter model achieves state-of-the-art performance across drug discovery benchmarks ...

2026-03-03 22:25 6400

Insilico Medicine and Liquid AI Announce Strategic Partnership Delivering Lightweight Scientific Foundation Models for Drug Discovery

AI-Powered R&D Acceleration: Insilico Medicine and CMS announce multiple collaborations in central nervous system and autoimmune diseases

CAMBRIDGE, Mass., Feb. 10, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinica...

2026-02-10 21:00 8043

Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development - Oncology

CAMBRIDGE, Mass., Feb. 6, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico") (3696.HK), a clinic...

2026-02-06 21:00 8925

Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications

* NLRP3 is a validated anti-inflammatory target that mediates the release of proinflammatory cyto...

2026-02-05 21:00 8317

Insilico Medicine Receives USD 5million Milestone Payment from Menarini Group Following First-in-Human (FIH) Achievement for MEN2501

Followed by the development and regulatory milestone payment of USD 3 million in July 2025, Insilic...

2026-02-03 22:00 7957

Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Cardiometabolic Therapies

CAMBRIDGE, Mass., Jan. 27, 2026 /PRNewswire/ -- Insilico Medicine, a clinical-stage biotechnology c...

2026-01-27 22:00 9038